|
Clinical trials Methodology/study design
Citations 51-60 of 93 total displayed.
|
Past content
(since Jan 2001):
|
- ARTICLES
Identification of potential CSF biomarkers in ALS
- G. M. Pasinetti, L. H. Ungar, D. J. Lange, S. Yemul, H. Deng, X. Yuan, R. H. Brown, M. E. Cudkowicz, K. Newhall, E. Peskind, S. Marcus, and L. Ho
Neurology 2006; 66: 1218-1222.
[Abstract]
[Full text]
[PDF]
- VIEWS & REVIEWS
Optimizing the ongoing search for new treatments for Parkinson disease: Using futility designs
- B. C. Tilley, Y. Y. Palesch, K. Kieburtz, B. Ravina, P. Huang, J. J. Elm, K. Shannon, G. F. Wooten, C. M. Tanner, G. C. Goetz on behalf of the NET-PD Investigators
Neurology 2006; 66: 628-633.
[Abstract]
[Full text]
[PDF]
- ARTICLES
A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS
- G. Levy, P. Kaufmann, R. Buchsbaum, J. Montes, A. Barsdorf, R. Arbing, V. Battista, X. Zhou, H. Mitsumoto, B. Levin, and J.L.P. Thompson
Neurology 2006; 66: 660-663.
[Abstract]
[Full text]
[PDF]
- ARTICLES
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
- The NINDS NET-PD Investigators
Neurology 2006; 66: 664-671.
[Abstract]
[Full text]
[PDF]
- BRIEF COMMUNICATIONS
Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
- F. Kimura, C. Fujimura, S. Ishida, H. Nakajima, D. Furutama, H. Uehara, K. Shinoda, M. Sugino, and T. Hanafusa
Neurology 2006; 66: 265-267.
[Abstract]
[Full text]
[PDF]
- EDITORIALS
Acute transverse myelitis: Is the "idiopathic" form vanishing?
- Bruce A.C. Cree and Dean M. Wingerchuk
Neurology 2005; 65: 1857-1858.
[Full text]
[PDF]
- BRIEF COMMUNICATIONS
Idiopathic acute transverse myelitis: Application of the recent diagnostic criteria
- J. de Seze, C. Lanctin, C. Lebrun, I. Malikova, C. Papeix, S. Wiertlewski, J. Pelletier, O. Gout, C. Clerc, C. Moreau, G. Defer, G. Edan, F. Dubas, and P. Vermersch
Neurology 2005; 65: 1950-1953.
[Abstract]
[Full text]
[PDF]
- CLINICAL/SCIENTIFIC NOTES
Saccade testing in the diagnosis and treatment of type 3 Gaucher disease
- S. Pensiero, A. Accardo, M. G. Pittis, G. Ciana, B. Bembi, and P. Perissutti
Neurology 2005; 65: 1837.
[Full text]
[PDF]
- BRIEF COMMUNICATIONS
Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data
- J. Sastre-Garriga, G. T. Ingle, M. Rovaris, N. Téllez, B. Jasperse, D. R. Altmann, B. Benedetti, V. L. Stevenson, M. Cercignani, S. M. Leary, F. Barkhof, B. Brochet, V. Dousset, M. Filippi, X. Montalban, N. F. Kalkers, C. H. Polman, À Rovira, D. H. Miller, and A. J. Thompson
Neurology 2005; 65: 633-635.
[Abstract]
[Full text]
[PDF]
- ARTICLES
A clinical rating scale for Batten disease: Reliable and relevant for clinical trials
- F. J. Marshall, E. A. de Blieck, J. W. Mink, L. Dure, H. Adams, S. Messing, P. G. Rothberg, E. Levy, T. McDonough, J. DeYoung, M. Wang, D. Ramirez-Montealegre, J. M. Kwon, and D. A. Pearce
Neurology 2005; 65: 275-279.
[Abstract]
[Full text]
[PDF]
|
|
